~~<i id='9679F01CB5'><strike id='9679F01CB5'><tt id='9679F01CB5'><pre id='9679F01CB5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

entertainment

author：hotspot 2025-10-01 17:18:51 - browse：97647

Michel Pairet -- health business coverage from STAT — Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Readout LOUD podcast: mifepristone case, GLP

explore

leisure time

focus

knowledge

focus

LaneTurner/GlobeStaffContemporarypaintingsbyartistswhohaveovercomehomelessnessordisabilitiesgreetvis

WSS

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Supreme Court mifepristone arguments center on docs' right to sue

How to fix the rural physician shortage in the U.S.

House looks to weaken Medicare negotiation

Decaf coffee targeted by food safety group under obscure FDA rule

Decaf coffee targeted by food safety group under obscure FDA rule

focus

entertainment

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

ChatGPT in medicine: STAT answers readers' burning questions

Medical device lobby: We're tired of waiting on Medicare coverage

Hollywood unions extend contract negotiations for actors

Covid isolation guidance eased by the CDC

Anesthesiologist group: stop taking Ozempic before surgery

Roche subsidiary Foundation Medicine opens new headquarters

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Vertex Pharmaceuticals may move headquarters in Boston

leisure time

An inside look at PIPEs, biotech's buzzy new financing tool

RaDonda Vaught to speak at CommonSpirit event on patient safety

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

States should stop sabotaging methadone treatment reform

Will generative AI in health care meet the fate of IBM's Dr. Watson?

Clinical trials giant ICON acquires HumanFirst

focus

knowledge

focus

focus